Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation
Histone deacetylase (HDAC) inhibitors are approved for cancer treatment and are being investigated for a wide range of other diseases. Despite their therapeutic promise, clinical studies have reported cardiac side effects, particularly electrocardiogram (EKG) abnormalities, with QT interval prolonga...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2026-05-01
|
| Sarja: | Cells |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2073-4409/15/10/902 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|